You are now moving to an external website.
Disclaimer
This link will lead you to leave the website of Chugai Pharma Taiwan; the content of the linked website you choose (links, changes, or updates in this website) is no longer the responsibility of Chugai Pharma Taiwan. Chugai Pharma Taiwan does not take any legal responsibility for the information transmitted by this linked website.
This link is for your convenience only, and any link does not mean that Chugai Pharma Taiwan endorses or approves its website content.

Access the link

Autoimmune
Actemra Solution for SC Injection
衛部菌疫輸字第000977號
Product Introduction
Actemra 162mg for SC Injection
Actemra 162mg for SC Injection

Indications:

1.Rheumatoid Arthritis(RA):

Actemra may be used as concomitantly with methotrexate (MTX) in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anit-Rheumatic Drugs (DMARD) or TNF Antagonist. ACTEMRA may be used as monotherapy, if the patients who have had an inadequate response to MTX.ACTEMRA has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate measured by HAQ-DI score.

Actemra 162mg for SC Injection
Actemra 162mg for SC Injection
Actemra 162mg for SC Injection
Actemra 162mg for SC Injection
2.Giant Cell Arteritis(GCA):

Actemra is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Product Specification
Product Name
Actemra 162mg for SC Injection